Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 89.25 percent increase over losses of $(0.93) per share from the same period last year. The company reported quarterly sales of $1.788 million which beat the analyst consensus estimate of $1.648 million by 8.53 percent. This is a 62.33 percent decrease over sales of $4.746 million the same period last year.